Articles

Currently, cholinesterase inhibitors are the mainstay in clinical practice of symptomatic treatment for Alzheimer’s disease (AD). They are believed...

In this article, we will consider the clinical, neurochemical, and pathological features of the various types of DLB, review therapeutic strategies...

A number of genetic and non-genetic factors may influence the development of AD. Mutations in genes on chromosomes 14, 1, and 21, which increase...

Treatment Response in Alzheimer's Disease Ever since the licensing of cholinesterase inhibitors (ChEIs) and memantine for the treatment of AD, there...

Treatment Response in Alzheimer’s DiseaseEver since the licensing of cholinesterase inhibitors (ChEIs) and memantine for the treatment of AD,...

Although there have been tremendous developments in the understanding of the molecular biology of Alzheimer’s disease (AD), this has not yet been...

The AD Neuroimaging Initiative Last fall, the NIA, a component of the National Institutes of Health (NIH), and its partners began funding the AD...

Acetylcholinesterase Inhibitors Research has shown that the amount of a chemical called acetylcholine diminishes in the brains of people with...